NOCIL LIMITED Fair Value
NOCIL · Chemicals · Current price ₹170.53
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹94 | 3% ROE fading to 13% over ~3 yrs, on ₹106 book |
| Relative P/E | ₹179 | EPS × 53.8 peer-median P/E |
| Graham floor | ₹89 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | ₹189 | Street consensus 12-month target price |
Is NOCIL LIMITED undervalued?
DocStoX estimates the fair value of NOCIL LIMITED at ₹127 per share, versus the current market price of ₹171. That puts the stock about -25.5% above our fair-value estimate, which we read as "Expensive". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹94), Relative P/E (₹179), Graham floor (₹89), Analyst target (₹189). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹89 (bear) to ₹127 (base) to ₹189 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on NOCIL LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.